×
About 469 results

ALLMedicine™ Acute Bronchospasm Center

Research & Reviews  37 results

Theophylline Level 
https://emedicine.medscape.com/article/2090395-overview

Feb 9th, 2020 - Reference Range Theophylline is a methylxanthine, a class of molecule similar to the xanthines caffeine and theobromine found in a normal diet. [1, 2] It has a half-life of 8 hours in a healthy person but decreases to 4-5 hours in people who smoke...

Theophylline Level 
https://emedicine.medscape.com/article/2090395-print

Feb 9th, 2020 - Theophylline is a methylxanthine, a class of molecule similar to the xanthines caffeine and theobromine found in a normal diet.[1, 2] It has a half-life of 8 hours in a healthy person but decreases to 4-5 hours in people who smoke.[3] In the blood...

Tissue traction microscopy to quantify muscle contraction within precision-cut lung sli...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7052683
American Journal of Physiology. Lung Cellular and Molecular Physiology; Ram-Mohan S, Bai Y et. al.

Nov 27th, 2019 - In asthma, acute bronchospasm is driven by contractile forces of airway smooth muscle (ASM). These forces can be imaged in the cultured ASM cell or assessed in the muscle strip and the tracheal/bronchial ring, but in each case, the ASM is studied ...

FDA approves benralizumab autoinjector for eosinophilic asthma
https://www.mdedge.com/pulmonary-health-hub/article/209478/asthma/fda-approves-benralizumab-autoinjector-eosinophilic?channel=94
Christopher Palmer

Oct 4th, 2019 - The Food and Drug Administration has approved a prefilled, single-use autoinjector of benralizumab (Fasenra) for self-administration in adults with eosinophilic asthma, according to a press release from AstraZeneca. Benralizumab is already approve.

Incidence of acute bronchospasm during systemic adenosine administration for coronary a...
https://doi.org/10.4997/JRCPE.2019.307
The Journal of the Royal College of Physicians of Edinburgh; Morrow A, Ford TJ et. al.

Sep 9th, 2019 - Adenosine is frequently used during coronary angiography to induce hyperaemia and allow operators to perform quantitative measurements of lesion severity. Acute bronchospasm is a recognised side effect relating to the activation of 'off target' A2...

see more →

Guidelines  1 results

NUCALA (mepolizumab) For Severe Eosinophilic Asthma
https://gskpro.com/en-us/products/nucala

NUCALA is indicated for the add-on maintenance treatment of patients 12 years and older with severe asthma with an eosinophilic phenotype. NUCALA is not indicated for the relief of acute bronchospasm or status asthmaticus.

see more →

Drugs  187 results see all →

Clinicaltrials.gov  237 results

Bevespi aerosphere - glycopyrrolate and formoterol fumarate aerosol, metered-AstraZeneca Pharmaceuticals LP
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ae02436e-9528-490e-a844-0c0f6f2843f9

Nov 4th, 2020 - BEVESPI AEROSPHERE is indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). Limitations of Use: BEVESPI AEROSPHERE is not indicated for the relief of acute bronchospasm or for the treatment of asthm...

Advair diskus - fluticasone propionate and salmeterol powder-GlaxoSmithKline LLC
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4eeb5f6a-593f-4a9e-9692-adefa2caf8fc

Oct 19th, 2020 - ADVAIR DISKUS is a combination product containing a corticosteroid and a long-acting beta2-adrenergic agonist (LABA) indicated for: •Twice-daily treatment of asthma in patients aged 4 years and older. (1.1) •Maintenance treatment of airflow obstru...

Fasenra - benralizumab injection, solution-AstraZeneca Pharmaceuticals LP
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=da6aca1a-19ed-44a4-abb7-696c7d58b784

Oct 12th, 2020 - FASENRA is indicated for the add-on maintenance treatment of patients with severe asthma aged 12 years and older, and with an eosinophilic phenotype [see Clinical Studies (14)]. Limitations of use: •FASENRA is not indicated for treatment of other ...

Nucala - mepolizumab injection, powder, for solution-GlaxoSmithKline LLC
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fefb887c-e4ac-431e-8893-e9d1a5a63fea

Sep 24th, 2020 - NUCALA is an interleukin-5 (IL-5) antagonist monoclonal antibody (IgG1 kappa) indicated for: •Add-on maintenance treatment of patients with severe asthma aged 6 years and older, and with an eosinophilic phenotype. (1.1) •The treatment of adult pat...

Fluticasone propionate and salmeterol diskus - fluticasone propionate and salmeterol powder-Prasco Laboratories
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6eb6ddac-fa26-43b3-bf3e-5b7b58138fdc

Sep 21st, 2020 - Fluticasone Propionate/Salmeterol DISKUS is a combination product containing a corticosteroid and a long-acting beta2-adrenergic agonist (LABA) indicated for: •Twice-daily treatment of asthma in patients aged 4 years and older. (1.1) •Maintenance ...

see more →

News  7 results

FDA approves benralizumab autoinjector for eosinophilic asthma
https://www.mdedge.com/pulmonary-health-hub/article/209478/asthma/fda-approves-benralizumab-autoinjector-eosinophilic?channel=94
Christopher Palmer

Oct 4th, 2019 - The Food and Drug Administration has approved a prefilled, single-use autoinjector of benralizumab (Fasenra) for self-administration in adults with eosinophilic asthma, according to a press release from AstraZeneca. Benralizumab is already approve.

FDA Approves Mepolizumab (Nucala) for Severe Asthma
https://www.medscape.com/viewarticle/853957

Nov 3rd, 2015 - The US Food and Drug Administration (FDA) approved mepolizumab (Nucala, GlaxoSmithKline) for use in combination with other medications for maintenance treatment of severe asthma in patients aged 12 years or older and with an eosinophilic phenotype...

FDA Approves Mepolizumab (Nucala) for Severe Asthma
https://www.staging.medscape.com/viewarticle/853957

Nov 3rd, 2015 - The US Food and Drug Administration (FDA) approved mepolizumab (Nucala, GlaxoSmithKline) for use in combination with other medications for maintenance treatment of severe asthma in patients aged 12 years or older and with an eosinophilic phenotype...

FDA Approves Long-Acting COPD Inhaler
https://www.medpagetoday.com/pulmonology/smokingcopd/47038

Aug 1st, 2014 - The FDA approved another once-daily bronchodilator, olodaterol (Striverdi Respimat), for maintenance treatment of chronic obstructive pulmonary disease (COPD). Approved indications for the long-acting beta-adrenergic agonist (LABA) drug included l...

May 2005
https://www.medscape.com/viewarticle/503848_7

May 3rd, 2005 - Pulmonology Agents Manufacturer: Schering Drug Approval Classification: Original New Drug Application (Approval Date: 3/30/05) Indication:  Asmanex Twisthaler (mometasone furoate) inhaler is indicated for the maintenance treatment of asthma as pro...

see more →